Biotech Kate Sheridan STAT Plus: With two new insurance partnerships, EQRx takes its first steps toward lowering drug prices. But how big are those steps?
Politics Rachel Cohrs STAT Plus: Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates
